

This listing of claims will replace all prior versions of claims in the application.

Claim 1. (original) A peptide derivative represented by the general formula (I) or a salt thereof:



wherein Z represents an aryl group which may or may not have a substituent or a heteroaryl group which may or may not have a substituent; n represents 0, 1 or 2; AA<sub>1</sub>-AA<sub>2</sub> represents Lys-Val or Arg-Leu; and R represents -OH or -NH<sub>2</sub>.

Claim 2. (currently amended) The peptide derivative or a salt thereof according to claim 1, where Z represents an aryl group which may or may not have a halogen atom, a lower alkyl group, a lower alkoxy group, phenyl group, a phenyl-lower alkyl group or nitro group as the substituent or a heteroaryl group which may or may not have a halogen atom, a lower alkyl group, a lower alkoxy group, phenyl group, a phenyl-lower alkyl group or nitro group as the substituent.

Claim 3. (currently amended) The peptide derivative or a salt thereof according to claim 1 or 2, where the aryl group is phenyl group or naphthyl group; and the heteroaryl group is furyl group, thienyl group, pyridyl group or quinolyl group.

Claim 4. (currently amended) A pharmaceutical composition comprising a peptide derivative or a salt thereof according to ~~claim 1~~ any one of claims 1 to 3, and a pharmaceutically acceptable carrier thereof.

Claim 5. (original) The pharmaceutical composition according to claim 4, which is a PAR-2-activating agent.

Claims 6-7. (cancelled)

Claim 8. (new) A method of treating a patient suffering from or susceptible to decrease of saliva secretion, the decrease of lacrimal fluid secretion or gastrointestinal disorder, comprising administering to the patient a peptide derivative or a salt thereof according to claim 1.

Claim 9. (new) The method of claim 8 wherein a patient is identified as suffering from decrease of saliva secretion, the decrease of lacrimal fluid secretion or gastrointestinal disorder and the peptide derivative or a salt thereof is administered to the identified patient.

Claim 10. (new) A method of treating a patient suffering from or susceptible to dysfunction of masticatory, dysphagia, dysgeusia (taste disorder), ozostomia, intra-oral cavity dysphoria, intra-oral cavity infection, intra-oral cavity inflammation, dry eye, ectocornea detachment, keratitis, corneal ulcer, conjunctivitis, stomach ulcer, duodenal ulcer, gastritis, diarrhea, enteritis or Sjogren's syndrome, comprising:  
administering to the patient a peptide derivative or a salt thereof according to claim 1.

Claim 11. (new) The method of claim 10 wherein the patient is identified as suffering from dysfunction of masticatory, dysphagia, dysgeusia (taste disorder), ozostomia, intra-oral cavity dysphoria, intra-oral cavity infection, intra-oral cavity inflammation, dry eye, ectocornea detachment, keratitis, corneal ulcer, conjunctivitis, stomach ulcer, duodenal ulcer, gastritis, diarrhea, enteritis or Sjogren's syndrome and the peptide derivative or a salt thereof is administered to the identified patient.